Novartis appoints Susanne Schaffert to lead oncology business

ZURICH: Novartis said it appointed company veteran Susanne Schaffert to lead its oncology unit from Jan. 1, replacing Liz Barrett who is stepping down to return to the United States.

Schaffert, who has been with Novartis for more than 20 years and has been part of its global oncology leadership team since 2013, will report to Chief Executive Vas Narasimhan and join the executive committee, the Swiss pharma group said in a statement on Thursday.

Barrett, a U.S. citizen who’d been at the helm of the unit since February 2018, said in the statement that she had accepted the role of CEO of a U.S. biotech firm because her family was unable to relocate to Basel, where Novartis’ oncology headquarters are based.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert